IMAC Holdings, Inc. Announces Research Scientist, Dr. Ian White, Joins IMAC Regeneration Centers As Chief Scientific Officer

Brentwood, TN, Sept. 13, 2018 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC”), a provider of regenerative rehabilitation orthopedic medical treatments without the use of surgery or opioids, announced that Dr. Ian White, Ph.D. has joined IMAC as the Chief Scientific Officer.

"We are excited to have Dr. Ian White join our team. We believe that with Dr. White on our team, we strengthen our ability to build and innovate scientific protocols involving cellular treatments. Adding Dr. White’s expertise to IMAC will enhance our ability to execute upon our vision and provide needed healthcare solutions to our patients to positively impact their quality of life," stated IMAC Founder, Dr. Matt Wallis.

Dr. White is an expert in the field of regenerative medicine with 20 years’ experience working with cardiovascular biology, tissue regeneration and stem cell biology.  Dr. White received his B.S. and M.S. degrees from Liverpool University, England prior to being hired at Dartmouth College to study the genetics of gamete biology. In August 2000, Dr. White was recruited to Harvard University to work with hematopoietic stem cells and immune cell biology under the mentorship of the world-renowned Dr. Laurie Glimcher, where he co-authored several peer-reviewed scientific manuscripts. Dr. White went on to receive his Ph.D. degree from the Ansary Stem Cell Institute of Cornell University under the guidance of Dr. Shahin Rafii. During this time Dr. White developed an in vitro method for culture expanding autologous stem cells in an artificial vascular niche for the treatment of cancer patients who have undergone bone marrow ablation following chemo- or radio-therapy. This technology has since gone on to be commercialized by Cornell University and has been described in several co-authored manuscripts and research grants awarded by the National Institutes of Health.

Following the completion of this Ph.D. work, Dr. White has spent time in the stem cell laboratory of Dr. Stephen Dalton, whose pioneering work led to the inclusion of c-myc as one of the four factors used by Nobel award winning Dr. Shinya Yamanaka in the generation of induced pluripotent stem cells.

Subsequently, Dr. White relocated to the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. Dr. White published ground-breaking research in the field of regenerative medicine alongside Dr. Joshua Hare, including a book chapter on the use of Mesenchymal Stem Cells (“MSCs”) in Cardiology. In 2015, Dr. White’s work on the regeneration of the heart was featured on the cover of Circulation Research, one of the top in the world, peer-reviewed journals for cardiovascular medicine. In 2016, Dr. White was honored with an award for the “Best Manuscript” by the American Heart Association for his work highlighting the role of peripheral nerves in cardiac regeneration. Dr. White has published extensively in the field of stem cell biology, clinical stem cell applications and regenerative medicine.

Following his appointment as the Company’s Chief Scientific Officer, Dr. Ian White commented: “I am very excited to be part of IMAC and utilize my research to further the treatments IMAC has to offer patients without the use of opioids or surgery.”

Dr. White is the Founder and President of BioFirma and was recently elected as the Chairman of the Scientific Committee for the American Association of Stem Cell Physicians.

“Dr. White has dedicated his career to advancements in regenerative medicine and we are very pleased that his expertise will help IMAC further develop proprietary research and treatments,” concluded Jeff Ervin, CEO of IMAC Holdings.

About IMAC Holdings, Inc.

IMAC Holdings was created in March 2015 to expand on the original IMAC Regeneration Center which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions.  We own or manage outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. We have partnered with several active and former professional athletes, opening two Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, and a Tony Delk IMAC Regeneration Center. Our outpatient medical clinics emphasize our focus around treating sports and orthopedic injuries without surgery or opioids.

Safe Harbor Statement
This press release contains forward-looking statements. These forward-looking statements, and terms such as “anticipate,” “expect,” “intend,” “believe,” “may,” “will,” “should,” or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, changing economic conditions. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will in fact occur.

More information about IMAC Holdings, Inc. is available at


Contact Data